Scinai

08/09/2026

Today we're sharing an update on our pipeline: Scinai will not be pursuing a new extension of our option and license arrangement with PinCell for PC111.

This wasn't driven by a new, negative scientific finding. Rather, it reflects disciplined portfolio and capital allocation. We're concentrating resources where we see the clearest combination of differentiation, development feasibility, and capital efficiency: scaling our CDMO business, Scinai Biopharma Services (Committed Customer Orders ~$3.1M as of Aug 16, on track toward our ~$5M 2026 revenue objective), and advancing our systemic IL-17 bispecific NanoAb to the next major milestone.

Amir Reichman, CEO, has more in the video below. We wish the PinCell team continued success advancing PC111.

Link to the PR: https://loom.ly/sXRn6eo

03/09/2026

Scinai's H1 2026 corporate overview and business update is now available on demand.

We were pleased to provide a market update across both engines of the business — continued momentum on the CDMO side, with 2026 committed customer orders now at ~$3.1M and an expanded U.S. clinical manufacturing program progressing, alongside progress updates on our immunology pipeline.

Amir Reichman, CEO: "Today, Scinai has two complementary value creating platforms, our Immunology R&D activities, and the borader CDMO business operating in Jerusalem and Yavne, Israel. The first half was largely about transforming the operating platform, and the second half is about demonstrating what we can do with it, such as converting customer activity to revenue, increasing utilization of the infrastructure, and advancing our R&D pipeline in a capital discipline way."

Catch the full replay: 🎥 YouTube: https://loom.ly/z4hbviI 🔁 LinkedIn Live replay: https://loom.ly/IxvRG7Y

24/08/2026

This morning we were happy to announce our corporate update and reported financial results for the six months ended June 30, 2026!

Several of the key milestones include:

• Committed Customer Orders reached approximately $3.1 million as of August 16, 2026, of which approximately $2.1 million had been invoiced.
• The Company is progressing an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical company, building on an existing contractual relationship and prior work performed through the customer's affiliate.
• Approximately $650 thousand in cash payments and advances have been received in connection with the expanded U.S. program, and substantive activities are underway while the definitive agreement covering the broader scope and commercial terms remains under negotiation.
• The expanded program is intended to support an investigational drug product toward U.S. IND submission and Phase III clinical development.
• The Company continues to pursue approximately $5 million in CDMO revenues for 2026

We are hosting an investor webinar this Wednesday (8/26) at 11 am ET where we will discuss these updates in more detail and share the outlook for the rest of 2026. You can sign up using this link: https://loom.ly/8IXnY7w

We hope to see you there!

Join Us Live! Scinai Mid-Year 2026 Business Update & Financial Resu...

15/07/2026

Recent FDA budget proposals signal continued momentum behind rare disease innovation.

Among the proposed initiatives is legislation that would make the Rare Pediatric Disease Priority Review Voucher (PRV) program permanent, providing greater long-term regulatory predictability and reinforcing the FDA’s commitment to encouraging innovation for patients with rare diseases.

While these proposals remain subject to congressional approval, they reflect a continued focus on supporting the development of therapies for conditions with significant unmet medical need.

At Scinai, we view this as an encouraging signal. Our development-stage anti-sFasL monoclonal antibody, PC111, is being advanced for severe orphan dermatological diseases, including pemphigus vulgaris and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), devastating conditions for which meaningful therapeutic innovation remains urgently needed.

We are proud to advance PC111 in collaboration with the exceptional team at Pincell. I would like to recognize CEO Amato, CSO Prof. Pincelli, Dr. Lotti, and Bennett for their scientific leadership, strategic vision, and dedication to advancing this promising therapeutic candidate. We look forward to continuing this collaboration as we work toward bringing new treatment options to patients with these devastating diseases.

Continued support for rare disease research and development helps foster an environment where innovative science can be translated into new treatment options for patients with limited therapeutic alternatives. We are excited to continue advancing our immunology pipeline and contributing to this important mission.

09/07/2026

AbbVie's recent $10.9B acquisition of Apogee Therapeutics is another strong signal that immunology remains one of biotech's most attractive strategic markets.

The transaction reinforces continued demand for differentiated biologics targeting immune-mediated diseases and highlights the value that large pharmaceutical companies continue to place on innovative immunology platforms.

For Scinai Immunotherapeutics (NASDAQ: SCNI), this is an encouraging backdrop as we continue to advance our proprietary VHH (NanoAb) platform.

What differentiates our approach is that we are not building a single therapeutic product. We are building a modular platform that enables multiple therapeutic architectures from the same underlying VHH technology, allowing us to tailor each product candidate to its intended clinical target product profile.

Our NanoAb platform is designed to support:

• Modular engineering of multi-specific antibodies, enabling the development of next-generation therapeutics targeting multiple disease pathways within a single molecule.
• Excellent physicochemical stability, supporting robust manufacturing while offering the potential for improved formulation, storage and distribution.
• Flexible molecular engineering, allowing us to optimize tissue exposure, pharmacokinetics and dosing strategies by selecting the molecular architecture best suited for the intended mechanism of action and route of administration, from locally delivered VHHs to long-acting systemic antibody formats.

This flexibility allows us to engineer therapies around the biology of each disease rather than relying on a one-size-fits-all antibody design.

Strategic transactions such as AbbVie's acquisition of Apogee continue to reinforce the long-term opportunity in immunology. We believe Scinai's differentiated NanoAb platform positions us well to create innovative therapeutics and to become an attractive partner for companies seeking next-generation immunology solutions.

24/06/2026

Among Scinai's pipeline assets, PC111 stands out as the company's flagship value driver.

PC111 is a first-in-class, fully-human, monoclonal antibody targeting soluble Fas Ligand (sFasL). PC111 is designed to treat severe, high-unmet-need dermatologic conditions, including Pemphigus and Stevens–Johnson syndrome / toxic epidermal necrolysis (SJS/TEN).

PC111 combines a differentiated mechanism with the advantages of an orphan indication, including the potential for regulatory incentives and an efficient development pathway.

In today's biotech environment, assets that combine clear unmet need, focused development pathways, and business development optionality are increasingly valuable. PC111 is positioned at that intersection.

10/06/2026

We are pleased to report our first quarter 2026 financial results!

Q1 2026 represented a tremendously important quarter for Scinai as we officially closed our hashtag of Recipharm Israel and Strategic hashtag with Recipharm. This allowed us to realize a tremendous increase not only in our total asset value but also in our total shareholder equity due to a gain from bargain purchase on the transaction of approximately $6.1M.

As we head into the 2H of 2026, Scinai is focused on scaling our CDMO platform, advancing pipeline programs toward key inflection points, and creating long-term shareholder value!

🔗 Link to the full earnings release in the comments section!

08/05/2026

📣 Save the Date!

Scinai Immunotherapeutics is pleased to announce that our CEO, Amir Reichman, and Head of R&D, Meital Portugal, will be speaking at the 7th Annual Dermatology Drug Development Summit Europe taking place May 19–21, 2026 in Amsterdam, Netherlands.

The Scinai team will be speaking on a panel titled: “Fast-Tracking Transformative Access to Differentiated Drugs”.

We look forward to joining industry leaders and innovators to discuss the future of dermatology drug development and advancing differentiated therapies for patients in need!

📍 Amsterdam, NL
📅 May 19–21, 2026

24/04/2026

This morning we announced a $2.61 million private placement financing led by institutional life sciences investor, with participation from new and existing investors.

This strategic capital is planned to support the expansion of our CDMO platform and advancement of customer programs.

You can view the full press release here: https://www.scinai.com/press-releases/scinai-immunotherapeutics-announces-261-million-private-placement-financing

22/04/2026

ICYMI: We DOUBLED our revenues!

For those of who didn’t have a chance to check out our earnings, watch the highlight clip below to hear the latest.

Not only did we double our revenues in 2025 vs the prior year, but we also significantly improved our cost structure and set up the company for a meaningful 2026, both in terms of expansion of our CDMO business as well as refining our R&D pipeline for our early-stage drug development.

Check out the clip to hear WHY we are tremendously excited for what’s to come in 2026!